Morgan Stanley Downgrades Novo Nordisk Over Patent Cliff

Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight, pointing to a subdued mid-term growth outlook and upcoming patent cliffs for semaglutide that threaten its core portfolio. Following the analyst report, shares fell 2.6% in early Copenhagen trading.

"The premium [is] more pronounced over GSK (10x) and Sanofi (8x)," wrote analysts led by Thibault Boutherin in a note discussing Novo's valuation relative to global peers facing similar loss-of-exclusivity issues.

Price Target and Near-Term Headwinds

Alongside the downgrade, Morgan Stanley maintained its price target of 250 Danish crowns. This target implies more than 10% downside from the stock's last closing price.

The investment bank's caution stems from a deceleration in expected financial performance. According to market coverage of the downgrade, Novo Nordisk is forecast to generate revenue and EBIT growth of just 2% to 3% in 2027.

Long-Term Growth Forecasts and Sector Comparison

Looking further ahead, analysts project a 4% compound annual growth rate for the Danish drugmaker from 2027 through 2030. This pace trails the broader European pharmaceutical sector, prompting questions about the sustainability of the company's growth model.

The core vulnerability centers on semaglutide, the active ingredient in Novo's blockbuster diabetes and obesity treatments. Data shows that semaglutide accounted for 75% of Novo's sales in 2026.

Understanding the Semaglutide Patent Cliff

A patent cliff occurs when a drug's patent protection expires, allowing generic competitors to enter the market and rapidly erode sales volumes and profit margins. For Novo Nordisk, the loss-of-exclusivity impact is scheduled to begin in 2031, with major patent expirations arriving across Europe and the United States in the early-to-mid 2030s.

Because a vast majority of the company's revenue relies on this single product line, analysts argue that the impending patent expirations pose a structural risk that is difficult to justify given the stock's current trading multiple compared to peers like GSK and Sanofi.